BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 35170453)

  • 21. [Risk factors of ISUP Modified Gleason score upgrading after radical prostatectomy].
    Li XD; Qu GY; Xu N; Xue XY; Wei Y; Zheng QS; Li JF; Cai H; Lin YZ
    Zhonghua Nan Ke Xue; 2016 May; 22(5):415-9. PubMed ID: 27416665
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Can
    Yin H; Chen M; Qiu X; Qiu L; Gao J; Li D; Fu Y; Huang H; Guo S; Zhang Q; Ai S; Wang F; Guo H
    Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3693-3701. PubMed ID: 33813594
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathological findings at radical prostatectomy of biopsy naïve men diagnosed with MRI targeted biopsy alone without concomitant standard systematic sampling.
    Luzzago S; Petralia G; Maresca D; Sabatini I; Cordima G; Brescia A; Verweij F; Garelli G; Mistretta FA; Cioffi A; Pricolo P; Alessi S; Ferro M; Matei DV; Renne G; de Cobelli O; Musi G
    Urol Oncol; 2020 Dec; 38(12):929.e11-929.e19. PubMed ID: 32600928
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy.
    Oh JJ; Hong SK; Lee JK; Lee BK; Lee S; Kwon OS; Byun SS; Lee SE
    BJU Int; 2012 Dec; 110(11 Pt B):E494-9. PubMed ID: 22540236
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
    Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
    BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and
    Franklin A; Yaxley WJ; Raveenthiran S; Coughlin G; Gianduzzo T; Kua B; McEwan L; Wong D; Delahunt B; Egevad L; Samaratunga H; Brown N; Parkinson R; Roberts MJ; Yaxley JW
    BJU Int; 2021 Jan; 127(1):71-79. PubMed ID: 32524748
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The prevalence and risk factors of upgrading of Gleason grade group between transrectal ultrasound prostate biopsy and prostatectomy specimens.
    Promsen W; Siriboonrid S; Binsri N; Kanjanatarayon S; Wiriyabanditkul W; Jiraanankul V
    Urol Ann; 2023; 15(1):18-21. PubMed ID: 37006215
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concordance of biopsy and pathologic ISUP grading in salvage radical prostatectomy patients for recurrent prostate cancer.
    Preisser F; Würnschimmel C; Pose RM; Heinze A; Steuber T; Michl U; Salomon G; Mandel P; Graefen M; Tilki D
    Prostate; 2022 Feb; 82(2):254-259. PubMed ID: 34807461
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathological features of Prostate Imaging Reporting and Data System (PI-RADS) 3 MRI lesions in biopsy and radical prostatectomy specimens.
    Rahota RG; Diamand R; Malavaud B; Fiard G; Descotes JL; Peltier A; Beauval JB; Roumeguère T; Roumiguié M; Albisinni S; Ploussard G
    BJU Int; 2022 May; 129(5):621-626. PubMed ID: 34358405
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Age and gleason score upgrading between prostate biopsy and radical prostatectomy: Is this still true in the multiparametric resonance imaging era?
    Mazzone E; Stabile A; Sorce G; Pellegrino F; Barletta F; Motterle G; Scuderi S; Cirulli GO; Cucchiara V; Brembilla G; Esposito A; Gandaglia G; Fossati N; De Cobelli F; Montorsi F; Karnes RJ; Guccini I; Briganti A
    Urol Oncol; 2021 Nov; 39(11):784.e1-784.e9. PubMed ID: 33865687
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intraductal carcinoma of the prostate (IDC-P) lowers apparent diffusion coefficient (ADC) values among intermediate risk prostate cancers.
    Currin S; Flood TA; Krishna S; Ansari A; McInnes MDF; Schieda N
    J Magn Reson Imaging; 2019 Jul; 50(1):279-287. PubMed ID: 30585372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of multiparametric magnetic resonance imaging to predict postoperative Gleason score upgrading in prostate cancer with Gleason score 3 + 4.
    Kim H; Kim JK; Hong SK; Jeong CW; Ku JH; Kwak C
    World J Urol; 2021 Jun; 39(6):1825-1830. PubMed ID: 32869150
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the Upgrading Rates of International Society of Urological Pathology Grades and Tumor Laterality in Patients Undergoing Standard 12-Core Prostate Biopsy versus Fusion Prostate Biopsy for Prostate Cancer.
    Demirtaş A; Sönmez G; Tombul ŞT; Demirtaş T; Akgün H
    Urol Int; 2019; 103(3):256-261. PubMed ID: 31242496
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and histopathological parameters in transrectal ultrasound-guided biopsies associated with tumor upgrading after radical prostatectomy: A comparative analysis of risk groups.
    Ozkaya M; Simsekoglu MF; Kalender G; Sahin KC; Gurses I
    Prostate; 2024 May; ():. PubMed ID: 38798171
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive Factors for Gleason Score Upgrading in Patients with Prostate Cancer after Radical Prostatectomy: A Systematic Review and Meta-Analysis.
    Wang Y; Chen X; Liu K; Liu R; Li L; Yin C; Song P
    Urol Int; 2023; 107(5):460-479. PubMed ID: 36990065
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cribriform morphology predicts upstaging after radical prostatectomy in patients with Gleason score 3 + 4 = 7 prostate cancer at transrectal ultrasound (TRUS)-guided needle biopsy.
    Keefe DT; Schieda N; El Hallani S; Breau RH; Morash C; Robertson SJ; Mai KT; Belanger EC; Flood TA
    Virchows Arch; 2015 Oct; 467(4):437-42. PubMed ID: 26229020
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Postoperative upgrading of prostate cancer in men ≥75 years: a propensity score-matched analysis.
    Herlemann A; Buchner A; Kretschmer A; Apfelbeck M; Stief CG; Gratzke C; Tritschler S
    World J Urol; 2017 Oct; 35(10):1517-1524. PubMed ID: 28493044
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low-volume grade group 2 prostate cancer candidates for active surveillance: a radical prostatectomy retrospective analysis.
    Björklund J; Cheung DC; Martin LJ; Komisarenko M; Lajkosz K; Hamilton RJ; Zlotta AR; Finelli A
    Scand J Urol; 2023; 57(1-6):29-35. PubMed ID: 36683418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature.
    Faisal FA; Sundi D; Pierorazio PM; Ball MW; Humphreys EB; Han M; Epstein JI; Partin AW; Carter HB; Bivalacqua TJ; Schaeffer EM; Ross AE
    BJU Int; 2014 Dec; 114(6b):E120-E129. PubMed ID: 24731026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined multiple clinical characteristics for prediction of discordance in grade and stage in prostate cancer patients undergoing systematic biopsy and radical prostatectomy.
    Liu H; Tang K; Xia D; Peng E; Wang L; Chen Z
    Pathol Res Pract; 2020 Nov; 216(11):153235. PubMed ID: 33035728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.